- Johnson & Johnson presented data for TECNIS PureSee IOL from a 293‑patient real‑world study (19 sites, Europe and Asia‑Pacific) and a 200‑patient randomized US trial (9 sites).
- Real‑world results: mean binocular uncorrected distance vision 20/19; 91% reported little/no glare, 93% little/no halos, 92% little/no starbursts; spectacle independence 96% distance, 95% intermediate, 61% near; 93% overall satisfaction.
- U.S. randomized trial: significantly improved intermediate and some near vision versus a monofocal, contrast sensitivity comparable to an aspheric monofocal, low visual symptoms, and 94% distance vision corrected to 20/25 or better with 97% patient satisfaction.
- High tolerance to residual postoperative refractive error: ametropic and emmetropic patients averaged binocular uncorrected distance vision 20/19, with distance spectacle independence 91% (ametropic) and 96% (emmetropic) and satisfaction 95% and 92%, respectively.
ASCRS presentations
Johnson & Johnson will present data for TECNIS PureSee IOL at the ASCRS Annual Meeting (April 10–13, 2026), reporting outcomes from a 293‑patient real‑world study and a 200‑patient randomized U.S. trial for the next‑generation extended depth‑of‑focus (EDOF) IOL.
Real‑world study (293 patients)
Multisite (19 sites, Europe and Asia‑Pacific) results showed mean binocular uncorrected distance vision of 20/19, low rates of bothersome visual symptoms (≈91% little/no glare, 93% little/no halos, 92% little/no starbursts), spectacle independence of 96% distance, 95% intermediate and 61% near, and 93% overall satisfaction; the lens demonstrated high tolerance to residual postoperative refractive error, with ametropic and emmetropic subgroups averaging binocular UDVA 20/19 and high satisfaction (95% and 92%).
U.S. randomized trial (200 patients)
Across nine U.S. sites, TECNIS PureSee delivered high‑quality distance vision, significantly better intermediate vision and some near vision gain versus a monofocal control, contrast sensitivity comparable to an aspheric monofocal (no clinically meaningful differences ≤0.3 log units), low visual disturbances, 94% corrected distance vision ≥20/25 and 97% patient satisfaction.
Indications and safety highlights
The IOL is indicated for primary implantation in adults to correct aphakia and mitigate presbyopia by extending depth of focus (PureSee for <1.0 D preexisting corneal astigmatism; PureSee Toric II for ≥1.0 D). Warnings/precautions include risk of reduced toric correction if rotated, need for careful preoperative evaluation, potential surgical risks (infection, inflammation, retinal detachment, increased IOP, hyphema, hypopyon, posterior capsular opacification), single‑use device handling and manual refraction recommendations.
